Key Takeaways
- IONM-guided parotidectomy significantly reduced operative time — 1.3 ± 0.2 h versus 1.8 ± 0.2 h in the unmonitored group (P < 0.05).
- Intraoperative Facial Nerve (FN) monitoring cut estimated blood loss to 50.3 ± 2.4 mL versus 75.8 ± 2.6 mL without monitoring (P < 0.05).
- Postoperative facial palsy occurred in 0% of monitored patients versus 14.3% (2/14) of unmonitored patients; seroma/salivary fistula occurred in 0% versus 7.1% (1/14). These complication differences did not reach statistical significance (P > 0.05) in this small cohort.
- A stimulation threshold of 0.15–0.40 mA reliably evoked intact FN responses, rising to 0.15–0.70 mA when the nerve was enveloped by soft tissue or tumor.
Clinical Context
Parotidectomy carries an inherent risk of Facial Nerve (FN) injury because of the nerve's intimate anatomical relationship with the gland. Reported postoperative FN injury rates in the literature range widely — from roughly 20% to 60% in international series — making nerve preservation one of the central technical challenges of parotid surgery. Intraoperative Neurophysiological Monitoring (IONM) offers a means of localizing the FN, mapping its branches, and confirming functional integrity before, during, and after tumor dissection.
This article summarizes clinical experience from a high-volume tertiary surgical center (Department of Otolaryngology, the First People's Hospital of Yongkang) drawn from 30 consecutive parotid tumor resections performed between May 2010 and October 2012. The objective was to determine whether IONM-assisted FN identification and dissection reduces surgical complications, operative time, and blood loss compared with conventional unmonitored dissection.
Clinical Evidence & Cohort Breakdown
Thirty patients with parotid tumors and no preoperative FN deficit were randomized into two groups. All operations were performed by the same surgeon, and the FN trunk and all branches were anatomically preserved in every case. Histopathology included pleomorphic adenoma (n = 16), myoepithelioma (n = 6), adenolymphoma (n = 6), B-cell lymphoma (n = 1), and basal cell adenoma (n = 1). Follow-up ranged from 0.5 to 3 years, with no recurrences in either group.
| Parameter | Group A (IONM) | Group B (No IONM) | Test Statistic | P Value |
|---|---|---|---|---|
| Patients (n) | 16 | 14 | — | — |
| Superficial / total parotidectomy | 14 / 2 | 13 / 1 | — | — |
| Seroma or salivary fistula | 0 (0%) | 1 (7.1%) | χ² = 1.182 | > 0.05 |
| Facial palsy | 0 (0%) | 2 (14.3%) | χ² = 2.449 | > 0.05 |
| Frey syndrome | 0 (0%) | 0 (0%) | — | — |
| Estimated blood loss (mL) | 50.3 ± 2.4 | 75.8 ± 2.6 | t = 27.929 | < 0.05 |
| Operative time (h) | 1.3 ± 0.2 | 1.8 ± 0.2 | t = 6.831 | < 0.05 |
Note: Of the two facial palsy cases in Group B, one was House-Brackmann grade II and one was House-Brackmann grade III. Overall FN injury rate across the entire cohort was 6.7% (2/30).
The overall FN injury rate of 6.7% compares favorably with previously reported rates of 21.9% and 36.4% in comparable domestic series and 20%–60% in international reports. The authors attribute this low rate to a combination of active FN dissection, a centripetal technique that first identifies the digastric branch, a predominantly benign case mix, and a majority of primary (single) operations.
Intraoperative IONM Protocol & Technical Pearls
The following step-by-step protocol reflects the technique used in the monitored cohort, using a Medtronic NIM-Response system.
- Anesthesia setup. Induce with intravenous fentanyl (2–4 µg/kg), propofol (2 mg/kg), and a single dose of the short-acting neuromuscular blocker succinylcholine (2 mg/kg) to facilitate endotracheal intubation. Maintain with propofol (3–6 µg/kg·min) and remifentanil (0.5–1.0 ng/kg·min). Do not redose neuromuscular blockade — succinylcholine's half-life is only a few minutes, so neuromuscular function has recovered by the time monitoring is required, eliminating Neuromuscular Blockade (NMB) Residual as a source of false-negative EMG responses.
- Electrode placement (four-channel technique). Place paired recording Subdermal Needle Electrodes in the frontalis, orbicularis oculi, nasolabial fold, and orbicularis oris. Place one reference needle electrode subcutaneously at the sternal manubrium and one at the shoulder. Secure all electrodes and connect via the interface box to the preamplifier, which amplifies the microvolt-level FN potentials to the monitor display. The four-channel configuration allows more precise assessment of the integrity of individual FN branches than the two-channel alternative (orbicularis oculi plus orbicularis oris only).
- Define a valid signal. Accept a waveform as a valid monitoring response only when EMG Amplitude exceeds 100 μV.
- Stimulation parameters. Use a Monopolar Stimulating Probe held perpendicular to the target tissue, applying stimulation for 1–2 s to evoke a response. Select a pulse duration of 50 μs (the system's optimal setting; the literature-cited optimum is 32 μs). Begin at 0.1 mA and never exceed 0.8 mA. Intact FN responses are typically evoked at 0.15–0.40 mA; when the nerve is covered by soft tissue or tumor, increase to 0.15–0.70 mA depending on tissue thickness.
- Surgical sequence. Expose the parotid-masseteric fascia, then enter the triangular fatty-connective-tissue compartment bounded by the posterior border of the parotid, the posterior belly of the digastric, and the floor of the external auditory canal. Identify the digastric branch of the FN at the anterior-superior border of the posterior digastric belly, then follow it posterosuperiorly to the FN trunk. Dissect peripherally from the trunk, mobilizing the gland off each branch in a top-down fashion, then selectively dissect the cervicofacial trunk and branches according to tumor location before removing the tumor en bloc with surrounding parotid tissue.
- Interpret and act on feedback. Use stimulation to map the nerve's course through soft tissue and tumor, to guide sharp dissection during nerve mobilization, and to confirm FN integrity before closure and thereby predict postoperative function.
- Recognize confounders. Interpret Loss of Signal (LOS) cautiously: electrocautery interference, mechanically evoked EMG from direct nerve traction, and poor electrode contact can all degrade sensitivity or specificity. IONM is an adjunct — it does not replace detailed anatomical knowledge, experienced judgment, and meticulous technique.
Clinical Implications for Surgeons & IONM Specialists
- IONM is associated with measurable efficiency gains. Even where complication rates did not differ statistically in this small sample, monitored cases were faster and bled less — consistent with more confident, targeted nerve identification and less exploratory dissection.
- The complication signal favors monitoring but is underpowered. Zero facial palsy and zero seroma/fistula in the monitored arm versus 14.3% and 7.1% respectively is clinically meaningful, but the study was not powered to detect significance for these endpoints. Larger trials are needed.
- Anesthetic discipline is non-negotiable. A single intubating dose of succinylcholine with no subsequent relaxant is the key to reliable, artifact-free EMG throughout dissection.
- Threshold-based interpretation matters. Expect intact responses at 0.15–0.40 mA on bare nerve; escalate current for tissue-covered segments rather than assuming nerve injury.
- Limitations to acknowledge. Short follow-up, small sample size, and single-surgeon/single-center design limit generalizability; the authors call for further basic and clinical research to confirm these findings.
Reference
Xu Z, Long Y, Lin K, Zhu N, Ying G. Preliminary observations in parotid tumor resection applicated with facial nerve monitoring. Chinese Archives of Otolaryngology-Head and Neck Surgery. 2014;21(1):31-33. DOI: 10.16066/j.1672-7002.2014.01.004.
Medical Disclaimer: This article is provided for educational and informational purposes only and does not constitute medical advice. Clinical decisions regarding Intraoperative Neurophysiological Monitoring and surgical technique should be individualized to each patient and made by qualified healthcare professionals in accordance with institutional protocols and current evidence-based guidelines.